Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-16T13:06:25.280Z Has data issue: false hasContentIssue false

Selective serotonin re-uptake inhibitors: use in depression

Published online by Cambridge University Press:  02 January 2018

I. N. Ferrier
Affiliation:
Department of Psychiatry, School of Neuroscience, University of Newcastle upon Tyne NE1 4LP
T. Silverstone
Affiliation:
Department of Psychological Medicine, St Bartholomew's Hospital, London EC1A 7BE
D. Eccleston
Affiliation:
Department of Psychiatry, School of Neuroscience, University of Newcastle upon Tyne NE1 4LP
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

This short review outlines the clinical profile of the selective serotonin re-uptake inhibitors (SSRIs). There has been much recent publicity and promotion of this group of drugs and this review attempts to give a balanced account of their current place in the treatment of depression. Although a large number of preclinical and clinical trials have been carried out many questions and problems remain – it is important to proceed carefully and carry out (and replicate) controlled independent clinical trials. The views of general psychiatrists and GPs about these drugs in normal clinical practice will be the acid test – this will be particularly important in view of their cost.

Information

Type
Keynotes
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists 1992
Submit a response

eLetters

No eLetters have been published for this article.